EUVIMEDEUVIMED entdecken
Crossref

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Nitin Rohatgi, Michael Rothe, Pam K Mangat iD, Elizabeth Garrett-Mayer iD, Funda Meric-Bernstam iD, Evan Pisick, Olatunji B Alese iD, Christopher M Reynolds, Ramya Thota iD, Gina M Vaccaro iD, Margaret von Mehren iD, Rebecca C Arend und 11 weitere

JCO Precision Oncology · 2023

DOI: 10.1200/po.23.00279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Nitin Rohatgi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Sutter Medical Center, Sacramento, CA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Melanoma. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with ATM mutations treated with nivolumab plus ipilimumab are reported. METHODS Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Primary end point was disease control (DC), defined as complete (CR) or partial (PR) response or stable disease (SD) of at least 16 weeks duration (SD16+). Low-accruing histology-specific cohorts with ATM mutations treated with nivolumab plus ipilimumab were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated based on a one-sided exact binomial test with a null DC rate of 15% versus 35% (power = .84; α = .10). Secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS Twenty-nine patients with 10 tumor types with ATM mutations were enrolled from January 2018 to May 2020. One patient was not evaluable for efficacy. One CR, three PR, and three SD16+ were observed for DC and OR rates of 24% ( P = .13; one-sided 90% CI: 14 to 100) and 14% (95% CI: 4 to 32), respectively. The null hypothesis of 15% DC rate was not rejected. Eleven patients had one treatment-related grade 3 adverse event (AE) or serious AE. There were two treatment-related patient deaths including immune-related encephalitis and respiratory failure. CONCLUSION Nivolumab plus ipilimumab did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with ATM mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMelanomaHumansNivolumabIpilimumabAntineoplastic Combined Chemotherapy ProtocolsMutationAtaxia Telangiectasia Mutated Proteins

Substanzen

NivolumabIpilimumabAntineoplastic AgentsATM protein, humanAtaxia Telangiectasia Mutated Proteins

Autor:innen und Institutionen

  • Sutter Medical Center, Sacramento, CA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • City of Hope Chicago, Zion, IL.
  • Winship Cancer Institute of Emory University, Atlanta, GA.
  • Michigan Cancer Research Consortium, Ypsilanti, MI.

ORCID-Profile: Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam, Olatunji B Alese, Ramya Thota, Gina M Vaccaro, Margaret von Mehren, Keely Hack, Alissa S Marr, Arthur Winer, Gina N Grantham, Dominique C Hinshaw, Abigail Gregory, Susan Halabi, Richard L Schilsky

Zitieren

APA

Rohatgi, N., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Meric-Bernstam, F., Pisick, E., Alese, O. B., Reynolds, C. M., Thota, R., Vaccaro, G. M., von Mehren, M., Arend, R. C., Chiu, V. K., Duvivier, H. L., Gold, P. J., Hack, K., Marr, A. S., Winer, A., Grantham, G. N., …, & Schilsky, R. L. (2023). Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. https://doi.org/10.1200/po.23.00279

Vancouver

Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, et al. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 2023. doi:10.1200/po.23.00279

BibTeX
@article{Rohatgi2023,
  author = {Rohatgi, Nitin and Rothe, Michael and Mangat, Pam K and Garrett-Mayer, Elizabeth and Meric-Bernstam, Funda and Pisick, Evan and Alese, Olatunji B and Reynolds, Christopher M and Thota, Ramya and Vaccaro, Gina M and von Mehren, Margaret and Arend, Rebecca C and Chiu, Vi K and Duvivier, Herbert L and Gold, Philip J and Hack, Keely and Marr, Alissa S and Winer, Arthur and Grantham, Gina N and Hinshaw, Dominique C and Gregory, Abigail and Halabi, Susan and Schilsky, Richard L},
  title = {Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.23.00279}
}
Kostenlos starten →